Skip to main content
Equibles

Scott Wasserman

Board Member

Inhibikase Therapeutics, Inc. (IKT)

Equibles does not estimate personal net worth.

Get an email with a short summary when Inhibikase Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get IKT alerts

About Scott Wasserman

Scott Wasserman is recorded as Board Member at Inhibikase Therapeutics, Inc. (IKT) since October 19, 2026. Inhibikase Therapeutics, Inc. reported in an 8-K filed October 20, 2026 that Scott Wasserman was appointed Class III director, effective October 19, 2026. Inhibikase Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inhibikase Therapeutics, Inc. includes Mark Iwicki (CEO and Board Member), Amit Munshi (Chairman and Board Member), Roberto Bellini (Chairman and Board Member) and 4 others.

“On October 19, 2026, the Board, upon the recommendation of the Board’s Corporate Governance and Nominating Committee, appointed Scott Wasserman to serve as a Class III director, to hold office until the Company’s annual meeting of stockholders in 2029 or until his earlier death, resignation or removal, effective as of October 19, 2026 (the “Appointment Date”).”
Inhibikase Therapeutics, Inc. Form 8-K, filed October 20, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at Inhibikase Therapeutics, Inc.

Recent activity